Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors

Immunotherapy for metastasized non‐small‐cell lung cancer (NSCLC) can show long‐lasting clinical responses. Selection of patients based on programmed death‐ligand 1 (PD‐L1) expression shows limited predictive value for durable clinical benefit (DCB). We investigated whether early treatment effects a...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Leest, Paul, Hiddinga, Birgitta, Miedema, Anneke, Aguirre Azpurua, Maria L., Rifaela, Naomi, ter Elst, Arja, Timens, Wim, Groen, Harry J. M., van Kempen, Léon C., Hiltermann, T. Jeroen N., Schuuring, Ed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564646/
https://www.ncbi.nlm.nih.gov/pubmed/34449963
http://dx.doi.org/10.1002/1878-0261.13090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564646/
https://www.ncbi.nlm.nih.gov/pubmed/34449963
http://dx.doi.org/10.1002/1878-0261.13090

Ejemplares similares